• Be responsible for corporate development strategy
• With more than 20 years of industrial operation management and investment experience, foresight of deeply planning pharmaceutical industry, entrepreneurial and initiative spirits, and strong resource integration capability
• Founded Chifeng Saliont pharmaceutical Co., Ltd. and Beijing PrimeGene Science and Technology Co., Ltd. successively in 2012
• Was awarded with “Outstanding Individual of Entrepreneurship” of the Nei Monggol Autonomous Region

• Be responsible for corporate strategy formulation, overall operation and clinical management
• Led the research and development of several projects, and NDA preparation and submission at Hua Medicine, and contributed to the company getting listed in Hong Kong in 2018
• Having worked at well-known multinational corporations such as Pfizer and GSK over 20 years, and with rich whole-process experience covering early research and development, clinical development and product launching
• Took charge of Phase I to IV clinical trials, medical affairs and drug safety management in the areas of dermatology, metabolism and neurology, and participated in the preparation and submission of several NDAs
• PhD of Albany Medical College, and bachelor of medicine of Peking University; US medical license
• Own 15 invention patents, and have published over 20 articles

• Responsible for the company's CMC, preparation research center, management center, strategic marketing and procurement department.
• Jiangzhong Health Products Co., Ltd., Sino-foreign joint venture Jiangxi Ronghe Pharmaceutical, Shanghai Dieselgard, etc. 40 years of pharmaceutical experience, good at the overall management of enterprises, development planning
• Jiangxi College of Traditional Chinese Medicine, Department of Pharmacy

• Responsible for the company's CMC center and formulation research center, guiding the establishment of topical formulation R&D platform.
• More than 20 years of experience in new product development and CMC team management in foreign multinational pharmaceutical companies, and experience in CMC R&D/manufacturing system leadership and management in domestic pharmaceutical companies. Experience in developing semi-solid, solid and injectable dosage forms, including special formulations, such as complex creams, nanoemulsions, nano-suspensions, oral controlled-release formulations, etc. Served as the director of API solid form strategy committee of multinational pharmaceutical companies
• Previously, he was in charge of formulation and CMC cross-disciplinary development of new products in Phase I-III clinical and commercialization phases at R&D centers of multinational pharmaceutical companies, such as Celgene, GSK, Pfizer, Eli Lilly, etc. He has been directly involved in or led the pharmacological development of several successful products.
• D. in Pharmacy from the University of Georgia, B.S. in Pharmacy from Peking University.

• Be responsible for the company’s quality assurance and commercial production management
• With rich experience of drug research and development, production management, quality control, technical management, industrialization and technology transfer, and pharmaceutical factory project planning and construction
• Having engaged in pharmaceutical industry for over 20 years, and worked at ZBD Pharmaceutical, Fujian Cosunter Pharmaceutical, and AOSAIKANG PHARM
• Master of pharmaceutical engineering of Nanjing Tech University

• Be responsible for administrative affairs of board office, market, and personnel management
• With rich experience of financial investment and business administration
• Having worked at large state-owned financial institutions for more than 10 years, such as Bank of Communications
• Master of finance of Shanxi University of Finance and Economics